PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
RRBN Presentera, N Shahb, A Alencarc, J Gersond, M Patele, W Jurczakf, K Patelg, A Matoh, C Cheahi, M Wangj
a Eli Lilly and Company (Lilly), São Paulo, SP, Brazil
b Medical College of Wisconsin, Milwaukee, United States
c Sylvester Comprehensive Cancer Center, Miami, United States
d University of Pennsylvania, Philadelphia, United States
e Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, United States
f Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
g Swedish Cancer Institute, Seattle, United States
h Memorial Sloan Kettering Cancer Center, New York, United States
i Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia
j MD Anderson Cancer Center, Houston, United States
Ver másLido
1324
Vezesque se leu este artigo
584
Total PDF
740
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 25 | 10 | 35 |
| 2025 5 | 68 | 11 | 79 |
| 2025 4 | 41 | 18 | 59 |
| 2025 3 | 52 | 11 | 63 |
| 2025 2 | 42 | 18 | 60 |
| 2025 1 | 24 | 16 | 40 |
| 2024 12 | 34 | 13 | 47 |
| 2024 11 | 26 | 18 | 44 |
| 2024 10 | 28 | 20 | 48 |
| 2024 9 | 37 | 20 | 57 |
| 2024 8 | 39 | 18 | 57 |
| 2024 7 | 35 | 21 | 56 |
| 2024 6 | 36 | 19 | 55 |
| 2024 5 | 32 | 23 | 55 |
| 2024 4 | 38 | 21 | 59 |
| 2024 3 | 19 | 19 | 38 |
| 2024 2 | 24 | 30 | 54 |
| 2024 1 | 12 | 13 | 25 |
| 2023 12 | 10 | 19 | 29 |
| 2023 11 | 13 | 26 | 39 |
| 2023 10 | 10 | 23 | 33 |
| 2023 9 | 13 | 19 | 32 |
| 2023 8 | 10 | 19 | 29 |
| 2023 7 | 7 | 40 | 47 |
| 2023 6 | 14 | 18 | 32 |
| 2023 5 | 7 | 12 | 19 |
| 2023 4 | 6 | 11 | 17 |
| 2023 3 | 5 | 9 | 14 |
| 2023 2 | 6 | 15 | 21 |
| 2023 1 | 6 | 6 | 12 |
| 2022 12 | 11 | 26 | 37 |
| 2022 11 | 7 | 18 | 25 |
| 2022 10 | 3 | 4 | 7 |
Mostrar tudo
